Galectin Therapeutics Inc.
NASDAQ:GALTBiotechnology
Healthcare
$2.98 +1.62%
+$0.05 today
- Market cap
- $196.25M
- Beta
- 0.49
- P/E (TTM)
- -7.1
- EPS (TTM)
- -$0.40
52W Low $1.85High $7.13
Volume 0.23M
Average 0.32M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$20.09M
FY 2025 · Annual
Net Income
-$30.84M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 23.82M | 31.74M | 32.13M | 36.57M | 14.29M |
| Selling, General & Admin | 6.36M | 6.62M | 5.94M | 5.86M | 5.8M |
| Operating Expenses | 30.18M | 38.35M | 38.07M | 42.43M | 20.09M |
| Depreciation & Amortization | 41K | 32K | 33K | 37K | 53K |
| EBITDA | (30M) | (37.71M) | (38.24M) | (41.47M) | (23.45M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (30.18M) | (38.35M) | (38.07M) | (42.43M) | (20.09M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 3K | 52K | 230K | 338K | 126K |
| Interest Expense | 489K | 1.03M | 2.79M | 5.54M | 7.33M |
| Other Income / Expenses | (348K) | (424K) | (2.99M) | (4.61M) | (10.75M) |
| Income Before Tax | (30.53M) | (38.78M) | (41.07M) | (47.05M) | (30.84M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (30.53M) | (38.78M) | (41.07M) | (47.05M) | (30.84M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.52) | (0.65) | (0.74) | (0.76) | (0.48) |
| EPS (Diluted) | (0.52) | (0.65) | (0.74) | (0.76) | (0.48) |
| 58.53M | 59.39M | 60.16M | 62.31M | 63.9M | |
| 58.53M | 59.39M | 60.16M | 62.31M | 63.9M |
GALT Earnings Waterfall · TTM
NASDAQ:GALT · Revenue to Net Income
Key Ratios
EPS$-0.41
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-8.5
P/S Ratio0.0
Analysis
$0 of revenue converted into -$26.3M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-0.41, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| ARS | ARS filing | Oct 13, 2026 | |
| DEF 14A | DEF 14A filing | Oct 13, 2026 | |
| DEFA14A | DEFA14A filing | Oct 13, 2026 | |
| PRE 14A | PRE 14A filing | Oct 2, 2026 | |
| 10-Q | Quarterly report | Aug 14, 2026 |
How much revenue does GALT generate?
Galectin Therapeutics Inc. (GALT) reported $0.00 of revenue in fiscal 2025.
Is GALT profitable?
Galectin Therapeutics Inc. (GALT) reported -$30.84M of net income.
Continue the stock analysis
Jump to another research area for this company.